These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12007566)

  • 1. Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release.
    Everett SA; Swann E; Naylor MA; Stratford MR; Patel KB; Tian N; Newman RG; Vojnovic B; Moody CJ; Wardman P
    Biochem Pharmacol; 2002 May; 63(9):1629-39. PubMed ID: 12007566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indolequinone bioreductive drugs: kinetic factors which influence selectivity for hypoxia.
    Everett SA; Naylor MA; Nolan J; Patel KB; Wardman P
    Anticancer Drug Des; 1998 Sep; 13(6):635-53. PubMed ID: 9755722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic activation of indolequinone-substituted 5-fluorodeoxyuridine prodrugs in hypoxic cells.
    Jiho Y; Kurihara R; Kawai K; Yamada H; Uto Y; Tanabe K
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1304-1307. PubMed ID: 30975626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro.
    Naylor MA; Swann E; Everett SA; Jaffar M; Nolan J; Robertson N; Lockyer SD; Patel KB; Dennis MF; Stratford MR; Wardman P; Adams GE; Moody CJ; Stratford IJ
    J Med Chem; 1998 Jul; 41(15):2720-31. PubMed ID: 9667963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones.
    Jaffar M; Everett SA; Naylor MA; Moore SG; Ulhaq S; Patel KB; Stratford MR; Nolan J; Wardman P; Stratford IJ
    Bioorg Med Chem Lett; 1999 Jan; 9(1):113-8. PubMed ID: 9990467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-electron reductive bioactivation of 2,3,5,6-tetramethylbenzoquinone by cytochrome P450.
    Goeptar AR; te Koppele JM; van Maanen JM; Zoetemelk CE; Vermeulen NP
    Biochem Pharmacol; 1992 Jan; 43(2):343-52. PubMed ID: 1310854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of biological one-electron reduction by (19)F NMR using hypoxia selective activation of an (19)F-labeled indolequinone derivative.
    Tanabe K; Harada H; Narazaki M; Tanaka K; Inafuku K; Komatsu H; Ito T; Yamada H; Chujo Y; Matsuda T; Hiraoka M; Nishimoto S
    J Am Chem Soc; 2009 Nov; 131(44):15982-3. PubMed ID: 19842623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emission under hypoxia: one-electron reduction and fluorescence characteristics of an indolequinone-coumarin conjugate.
    Tanabe K; Hirata N; Harada H; Hiraoka M; Nishimoto S
    Chembiochem; 2008 Feb; 9(3):426-32. PubMed ID: 18224643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
    Patterson AV; Barham HM; Chinje EC; Adams GE; Harris AL; Stratford IJ
    Br J Cancer; 1995 Nov; 72(5):1144-50. PubMed ID: 7577460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554).
    Aboagye EO; Lewis AD; Tracy M; Workman P
    Biochem Pharmacol; 1997 Dec; 54(11):1217-24. PubMed ID: 9416972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (13)C-labeled indolequinone-DTPA-Gd conjugate for NMR probing cytochrome:P450 reductase-mediated one-electron reduction.
    Komatsu H; Tanabe K; Nishimoto S
    Bioorg Med Chem Lett; 2011 Jan; 21(2):790-3. PubMed ID: 21168332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinone bioreductive prodrugs as delivery agents.
    Jaffar M; Abou-Zeid N; Bai L; Mrema I; Robinson I; Tanner R; Stratford IJ
    Curr Drug Deliv; 2004 Oct; 1(4):345-50. PubMed ID: 16305396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
    Hasinoff BB; Begleiter A
    Free Radic Res; 2006 Sep; 40(9):974-8. PubMed ID: 17015278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.
    Plumb JA; Gerritsen M; Workman P
    Br J Cancer; 1994 Dec; 70(6):1136-43. PubMed ID: 7526885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions.
    Saunders MP; Jaffar M; Patterson AV; Nolan J; Naylor MA; Phillips RM; Harris AL; Stratford IJ
    Biochem Pharmacol; 2000 Apr; 59(8):993-6. PubMed ID: 10692564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs.
    Dragovich PS; Broccatelli F; Chen J; Fan P; Le H; Mao W; Pillow TH; Polson AG; Wai J; Xu Z; Yao H; Zhang D
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5300-5304. PubMed ID: 29079474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting the Inherent Photophysical Properties of the Major Tirapazamine Metabolite in the Development of Profluorescent Substrates for Enzymes That Catalyze the Bioreductive Activation of Hypoxia-Selective Anticancer Prodrugs.
    Shen X; Laber CH; Sarkar U; Galazzi F; Johnson KM; Mahieu NG; Hillebrand R; Fuchs-Knotts T; Barnes CL; Baker GA; Gates KS
    J Org Chem; 2018 Mar; 83(6):3126-3131. PubMed ID: 29461834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species.
    Bailey SM; Lewis AD; Patterson LH; Fisher GR; Knox RJ; Workman P
    Biochem Pharmacol; 2001 Aug; 62(4):461-8. PubMed ID: 11448456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation.
    Jain M; Kwon CH
    J Med Chem; 2003 Dec; 46(25):5428-36. PubMed ID: 14640551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.